The short version: fast on appetite, slow on the scale
GLP-1 medications work on two different clocks. The appetite clock is fast: because a subcutaneous dose of semaglutide reaches peak blood concentration in about 1 to 3 days and the drug has a roughly one-week half-life, some people notice reduced hunger, earlier fullness, and fewer food cravings within the first days to weeks (StatPearls / clinical pharmacokinetics reviews, 2024). Cleveland Clinic endocrinologist W. Scott Butsch notes these once-weekly injections "usually reach their maximum effectiveness in about 72 hours," but also cautions that you may not notice an appetite change after the first dose and that "the initial dose of the medication may not have any effect" (Cleveland Clinic, 2025).
The weight clock is slow. Blood levels of the drug only reach steady state after about 4 to 5 weeks of weekly dosing, and doses are then raised in stages over several more months. In the pivotal STEP-1 trial, weight loss was measurable from the first check at week 4 but did not bottom out until roughly week 60. So it is completely normal for appetite to change in week one or two while the number on the scale moves slowly for months.
This page describes what happened on average in clinical trials. Your own timeline depends on your dose, your starting weight, your body's response, and lifestyle factors, and none of this is a substitute for guidance from your prescriber.
What happens in the first few days and weeks
In the earliest phase, most of what you may notice is on appetite and digestion, not weight. GLP-1 receptor agonists slow how quickly the stomach empties, increase satiety signaling, and reduce appetite and food cravings (StatPearls, 2024). A dedicated 20-week appetite substudy of semaglutide 2.4 mg found participants ate about 35% less at a test meal and reported less hunger, more fullness, and fewer and weaker cravings compared with placebo (Friedrichsen et al., Diabetes, Obesity and Metabolism, 2021).
Timing varies a lot between people. Cleveland Clinic frames it plainly: "The effects can be experienced within the first few days, whether that's an effect on your appetite or side effects like nausea, vomiting or diarrhea," but it may also take a few weeks and several doses for a full effect (Cleveland Clinic, 2025). Early GI side effects such as mild nausea are common and, in the semaglutide trial, were typically transient and mild-to-moderate and tended to subside over time (STEP-1, NEJM 2021).
A key point for expectations: the starting dose is intentionally low (a "sub-therapeutic" priming dose) to help your gut adjust. Little or no appetite change in the very first weeks does not mean the medication won't work at higher doses.
Timeline: what to expect week by week
The table below combines FDA-label dose schedules with the average weight-loss curve reported in the pivotal obesity trials (STEP-1 for semaglutide 2.4 mg; SURMOUNT-1 for tirzepatide). These are trial averages, not promises; individual results in the same trials varied widely. Treat every row as general education, not a treatment plan.
Why weight loss is gradual: the titration schedule
The slow build is by design. Both FDA labels tell prescribers to start low and increase the dose in 4-week steps specifically "to minimize gastrointestinal adverse reactions" (Wegovy and Zepbound prescribing information, 2024-2025). Jumping to a full dose would raise the risk of significant nausea and vomiting.
For Wegovy (semaglutide 2.4 mg), the label schedule is 0.25 mg for weeks 1-4, 0.5 mg for weeks 5-8, 1 mg for weeks 9-12, 1.7 mg for weeks 13-16, then the 2.4 mg (or 1.7 mg) maintenance dose from week 17 onward. That means most people do not reach a full maintenance dose until roughly month 4. Ozempic, the type 2 diabetes version of semaglutide, uses a different schedule and is not FDA-approved for weight loss, though it is the same active molecule.
For Zepbound (tirzepatide), the label starts at 2.5 mg once weekly for 4 weeks, then 5 mg, with further increases of 2.5 mg after at least 4 weeks on the current dose, up to maintenance doses of 5, 10, or 15 mg (maximum 15 mg). Because the higher doses drive more weight loss, reaching them takes several months of stepwise increases.
If a dose isn't tolerated, the labels allow delaying escalation by 4 weeks, which can stretch the timeline further. Dose decisions belong to your prescriber, who balances tolerability against response.
Semaglutide (Wegovy) trial timeline: the STEP-1 curve
STEP-1 was the 68-week, placebo-controlled trial that supported Wegovy's obesity approval (Wilding et al., New England Journal of Medicine, 2021; 1,961 adults with obesity or overweight, without diabetes). It gives the clearest picture of the semaglutide weight-loss curve over time.
The headline result: average weight change at week 68 was -14.9% with semaglutide 2.4 mg versus -2.4% with placebo. Crucially for timing, the authors report that weight loss was observed from the first post-randomization assessment (week 4) onward and reached its nadir around week 60 — meaning the average participant kept losing for well over a year before leveling off.
By week 68, the proportion of participants reaching each milestone was: 86.4% lost at least 5%, 69.1% lost at least 10%, 50.5% lost at least 15%, and 32.0% lost at least 20% of body weight (versus 31.5%, 12.0%, 4.9%, and 1.7% on placebo). A separate 20-week substudy showed an average 9.9% loss by week 20 on the 2.4 mg regimen (Friedrichsen et al., 2021) — a useful mid-journey signpost.
Tirzepatide (Zepbound) trial timeline: the SURMOUNT-1 curve
SURMOUNT-1 was the 72-week, placebo-controlled trial behind tirzepatide's obesity approval (Jastreboff et al., New England Journal of Medicine, 2022; 2,539 adults with obesity or overweight, without diabetes), with a 20-week dose-escalation phase before the maintenance period.
Average weight loss at week 72 rose with dose. On the treatment-regimen estimand, the results were about -15.0% at 5 mg, -19.5% at 10 mg, and -20.9% at 15 mg, versus -3.1% with placebo. On the efficacy estimand (effect while actually taking the drug), the figures were higher — roughly 16.0%, 21.4%, and 22.5%.
Milestone rates at week 72 (treatment-regimen estimand): at least 5% loss was reached by 85% (5 mg), 89% (10 mg), and 91% (15 mg); at least 20% loss by 30%, 50%, and 57% respectively, versus about 3% on placebo. As with semaglutide, these gains accumulate across the full trial, not in the first weeks.
Plateaus: when weight loss levels off
A plateau is expected, not a failure. In STEP-1, the average weight nadir came around week 60 — after that, weight tended to hold rather than keep dropping (Wilding et al., 2021). In SURMOUNT-1, weight loss on the 15 mg dose was essentially the same at week 176 (-22.9%) as at week 72 in the same group, illustrating a plateau-then-maintenance pattern (SURMOUNT-1 3-year results, 2024).
These medications are studied as long-term treatments for a chronic condition. Withdrawal trials (STEP-4 for semaglutide and SURMOUNT-4 for tirzepatide) found that stopping the drug generally led to substantial weight regain, which is why clinicians frame GLP-1s as ongoing therapy rather than a short course. Whether, when, and how to continue, adjust, or stop is a decision for you and your prescriber.
When to check in with a clinician
Because response varies, prescribers typically set checkpoints rather than waiting a full year. Cleveland Clinic's Dr. Butsch notes that losing more than 5% of body weight in the first 3 to 4 months on an obesity medication makes you more likely to maintain that loss at 12 months, and that with tirzepatide, 10% to 15% loss by 6 months predicts keeping it off after a year (Cleveland Clinic, 2025). This is why the first few months matter as a signal, even though the full effect takes longer.
General reasons people revisit their clinician include: little or no appetite change or weight movement after reaching a full maintenance dose; side effects that aren't settling; a plateau that arrives earlier or lower than hoped; or questions about diet, activity, and other medications. Your prescriber may consider adjusting the dose, the escalation pace, or the overall plan.
Seek prompt medical attention for warning signs described in the drug labels, such as severe or persistent abdominal pain (a possible sign of pancreatitis), signs of gallbladder problems, or a severe allergic reaction. This page cannot tell you to start, stop, or change any medication or dose — only a licensed clinician who knows your history can do that.
Why timelines differ — and two things that don't count
Even in tightly controlled trials, weight loss, appetite change, and side effects varied widely from person to person (Cleveland Clinic, 2025). Factors that influence your timeline include your current dose and how far along the escalation schedule you are, your starting weight, and — importantly — diet, physical activity, and sleep. Every pivotal trial paired the drug with a reduced-calorie diet and increased activity, and the labels indicate the medications are meant to be used alongside those changes.
Two things that are not the same as an FDA-approved GLP-1 timeline. First, compounded semaglutide or tirzepatide is not an FDA-approved finished drug; compounded products are not reviewed by the FDA for safety, effectiveness, or quality, so their potency and results can differ from the brand medications the trials studied. Second, supplements marketed as a "natural Ozempic" — berberine, for example — are not FDA-approved to treat obesity, are not equivalent to prescription GLP-1s, and the FDA does not evaluate supplement claims for weight-loss efficacy. Neither should be treated as a substitute or a reliable comparison for the trial timelines above.